类风湿关节炎与银屑病关节炎主要心血管事件的发生率及危险因素:一项基于人群的队列研究
该研究基于全市数据库纳入2006年1月至2015年12月诊断的类风湿关节炎(RA)和银屑病关节炎(PsA)患者,随访至2018年底,共13,905例(RA 12,233例,PsA 1,672例),累计119,571患者年随访后934例(6.7%)发生首次主要心血管不良事件(MACE)。RA与PsA调整后发生率相似(发生率比0.96,95%CI 0.75-1.22,P=0.767)。调整传统心血管危险因素、时间变化的ESR和CRP水平及糖皮质激素使用后,ESR、CRP和糖皮质激素使用与两个队列MACE风险升高独立相关;RA中甲氨蝶呤和NSAIDs使用与较少MACE相关,生物制剂DMARDs在两个队列中均与MACE无关。
要点
- RA与PsA患者MACE调整后发生率相似(发生率比0.96,95%CI 0.75-1.22,P=0.767)。
- 时间变化的ESR、CRP水平及糖皮质激素使用在两个队列中均与MACE风险升高独立相关。
- RA中甲氨蝶呤和NSAIDs使用与较少MACE相关,生物制剂DMARDs在两个队列中均与MACE无关。
核心结论
- RA与PsA的MACE发生率相似。
- 全身性炎症和糖皮质激素使用独立增加炎症性关节炎患者的MACE风险,而甲氨蝶呤和NSAIDs使用在RA中对MACE发生具有保护作用。
研究设计与样本
- 基于人群的回顾性队列研究,从全市数据库识别RA和PsA患者,纳入2006年1月至2015年12月招募的所有患者,随访至2018年底。
- 共纳入13,905例患者(RA 12,233例,PsA 1,672例),累计随访119,571患者年。
- 结局为首次MACE发生,关注协变量包括传统心血管危险因素、炎症标志物和药物治疗,采用时间依赖Cox比例风险模型识别MACE的独立预测因素。
主要发现
- 随访期间934例(6.7%)患者发生首次MACE。
- RA与PsA调整后发生率相似(发生率比0.96,95%CI 0.75-1.22,P=0.767)。
- 调整传统心血管危险因素、时间变化的ESR和CRP水平及糖皮质激素使用后,ESR、CRP和糖皮质激素使用在两个队列中均与MACE风险升高独立相关。
- RA中甲氨蝶呤和NSAIDs使用与较少MACE相关。
- 生物制剂DMARDs使用在RA和PsA中均与MACE无关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the incidence and risk factors of major adverse cardiovascular events (MACE) in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients. METHODS: A population-based retrospective cohort of RA and PsA patients was identified in a citywide database. All patients recruited from Jan 2006 to Dec 2015 were followed until the end of 2018. The outcome was the occurrence of a first MACE. Covariates of interest included traditional cardiovascular (CV) risk factors, inflammatory markers and pharmacotherapies. The independent predictors of MACE were identified by the time-dependent cox proportional hazard models. RESULTS: A total of 13,905 patients (12,233 RA and 1,672 PsA) were recruited. After a total of 119,571 patient-years of follow-up, 934 (6.7%) patients developed a first MACE. RA and PsA patients had similar adjusted incidence (incidence rate ratio 0.96, 95 % CI 0.75-1.22, p = 0.767). After adjusting for traditional CV risk factors, the time-varying erythrocyte sedimentation (ESR) rate and C-reactive protein (CRP) levels, and the use of glucocorticoids were independently associated with higher risk of MACE in both the RA and PsA cohorts. In RA, the use of methotrexate and non-steroidal anti-inflammatory drugs (NSAIDs) were associated with fewer MACE. The use of biologic disease modifying anti-rheumatic drugs was not associated with MACE in both RA and PsA. CONCLUSION: The incidence of MACE was similar in RA and PsA. Systemic inflammation and glucocorticoid use independently increased the risk of MACE in inflammatory arthritis, while methotrexate and NSAIDs use were protective against the development of MACE in RA.
引用
- Meng H, Lam SH, So H, et al. Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study. Semin Arthritis Rheum. 2024. PMID: 38368730. doi:10.1016/j.semarthrit.2024.152416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。